Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant.

Sikandar AilawadhiAugustina OgbonnayaSharanya MurtyDasha CherepanovBridgette Kanz SchroaderDorothy RomanusEileen FarrellyAjai Chari

Published in: Cancer medicine (2022)

Dose-attenuated 1LT was associated with longer DOT among patients with non-SCT NDMM. Each additional month of 1LT was associated with a reduced adjusted likelihood of disease progression and death at 2 years. Dose-attenuation of 1LT can extend DOT; longer DOT may improve clinical outcomes.

Keyphrases

newly diagnosed
stem cells
end stage renal disease
multiple myeloma
ejection fraction
chronic kidney disease
energy transfer
peritoneal dialysis
prognostic factors
mesenchymal stem cells
cell therapy